Eupraxia Financial Statements From 2010 to 2025
| EPRX Stock | CAD 7.40 0.08 1.09% |
Check Eupraxia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eupraxia Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Eupraxia financial statements analysis is a perfect complement when working with Eupraxia Pharmaceuticals Valuation or Volatility modules.
Eupraxia |
Eupraxia Pharmaceuticals Company Shares Outstanding Analysis
Eupraxia Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Eupraxia Pharmaceuticals Shares Outstanding | 35.85 M |
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Eupraxia Pharmaceuticals has 35.85 M of shares currently outstending. This is 80.14% lower than that of the Biotechnology sector and 66.45% lower than that of the Health Care industry. The shares outstanding for all Canada stocks is 93.73% higher than that of the company.
Eupraxia Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eupraxia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eupraxia Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eupraxia Pharmaceuticals competition to find correlations between indicators driving Eupraxia Pharmaceuticals's intrinsic value. More Info.Eupraxia Pharmaceuticals is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Eupraxia Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eupraxia Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Eupraxia Pharmaceuticals Financial Statements
Eupraxia Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Eupraxia Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. EUPRAXIA PHARMACEUTICALS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 19 people.
Pair Trading with Eupraxia Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eupraxia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eupraxia Stock
| 0.89 | MSFT | Microsoft CDR | PairCorr |
| 0.89 | MSFT | Microsoft Corp CDR | PairCorr |
| 0.72 | GOOG | Alphabet CDR | PairCorr |
| 0.72 | GOOG | Alphabet CDR | PairCorr |
Moving against Eupraxia Stock
The ability to find closely correlated positions to Eupraxia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eupraxia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eupraxia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eupraxia Pharmaceuticals to buy it.
The correlation of Eupraxia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eupraxia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eupraxia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eupraxia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.